GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Minocycline

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
IV label daily ceiling versus institutional loading and high-dose practice

The MINOCIN IV label sets a renal-impairment ceiling of 200 mg per 24 hours. UCSF lists a 200-mg loading dose followed by 100 mg every 12 hours without renal adjustment, and selected higher-dose treatment with specialist input. Initial-day exposure or high-dose maintenance can exceed the label ceiling.

Before applying: This is a real exposure difference, not just alternate wording. Obtain infectious-disease/antimicrobial-stewardship input and document the exact IV product, indication, renal status, total first-day exposure and monitoring before choosing an approach. Do not silently merge the label cap with an institutional schedule.

Also check: IV label daily ceiling versus institutional loading and high-dose practice

Official source

Minocycline - MINOCIN IV renal label

Product / population
Adult MINOCIN intravenous formulation; not acne extended-release tablets or capsules.
Renal measure
CrCl, mL/min; renal total-daily-dose ceiling.

Renal dosing, restrictions and evidence limits

The label describes incompletely characterized pharmacokinetics at CrCl below 80 mL/min and limits the total dose in renal impairment to 200 mg per 24 hours. Monitor BUN and creatinine. This IV formulation contains magnesium sulfate; monitor serum magnesium in renal impairment. The usual adult non-renal regimen is a 200-mg initial dose followed by 100 mg every 12 hours over 60 minutes, but do not automatically apply that loading exposure above the renal daily cap. See the separately displayed institutional regimen and documented difference.

Source revision: Prescribing text revised March 2025 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

Minocycline - MINOCIN IV renal label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult MINOCIN intravenous formulation; not acne extended-release tablets or capsules.

Renal method: CrCl, mL/min; renal total-daily-dose ceiling.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

UCSF - systemic minocycline institutional strategy

Adults; systemic immediate-release oral or IV minocycline institutional regimen.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

institutional regimen

IV label daily ceiling versus institutional loading and high-dose practice

The MINOCIN IV label sets a renal-impairment ceiling of 200 mg per 24 hours. UCSF lists a 200-mg loading dose followed by 100 mg every 12 hours without renal adjustment, and selected higher-dose treatment with specialist input. Initial-day exposure or high-dose maintenance can exceed the label ceiling.

How to use this: This is a real exposure difference, not just alternate wording. Obtain infectious-disease/antimicrobial-stewardship input and document the exact IV product, indication, renal status, total first-day exposure and monitoring before choosing an approach. Do not silently merge the label cap with an institutional schedule.

Minocycline - MINOCIN IV renal labelUCSF - systemic minocycline institutional strategyMinocycline extended-release (XIMINO)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeMinocycline - MINOCIN IV renal labelUCSF - systemic minocycline institutional strategy
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Oral immediate-release source; do not transfer to IV or extended-release minocycline. Historical infection regimens are not current preferred-therapy determinations.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/minocycline/

Usual oral dosing and original indication-specific regimens

Immediate-release oral tablets: 200 mg initially, then 100 mg every 12 hours. Alternative: two or four 50 mg tablets initially, then 50 mg four times daily.

Historical uncomplicated gonococcal infection other than male urethritis/anorectal infection: 200 mg initially, then 100 mg every 12 hours for at least 4 days; culture 2-3 days after treatment. Male uncomplicated gonococcal urethritis: 100 mg every 12 hours for 5 days. Syphilis: usual dosing for 10-15 days with close laboratory follow-up. Meningococcal carriage: 100 mg every 12 hours for 5 days.

Limited M. marinum cases used 100 mg every 12 hours for 6-8 weeks; optimum dose was not established. Adult uncomplicated urethral/endocervical/rectal C. trachomatis or U. urealyticum infection: 100 mg orally every 12 hours for at least 7 days. Take capsules/tablets with sufficient fluid to reduce esophageal irritation/ulceration.

GRPH-minocycline-01 · Source section: Usual oral dosing and original indication-specific regimensRenal section finder

Renal Dosing

The GlobalRPh discussion suggests lower doses or longer intervals, blood concentration not exceeding 15 micrograms/mL, and maximum 200 mg/day. The cited label narrative states that pharmacokinetics below CrCl 80 mL/min were incompletely characterized and data insufficient to determine adjustment; maximum 200 mg/24 hours, with BUN/creatinine monitoring because of tetracycline anti-anabolic effects.

GRPH-minocycline-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Specific recommendations are unavailable.

GRPH-minocycline-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Minocycline - MINOCIN IV renal label

Open original reference

Open / share this exact local source

DailyMed / NLM; manufacturer prescribing information · Adult MINOCIN intravenous formulation; not acne extended-release tablets or capsules.

Renal method: CrCl, mL/min; renal total-daily-dose ceiling.
Source date: Prescribing text revised March 2025
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The label describes incompletely characterized pharmacokinetics at CrCl below 80 mL/min and limits the total dose in renal impairment to 200 mg per 24 hours. Monitor BUN and creatinine. This IV formulation contains magnesium sulfate; monitor serum magnesium in renal impairment. The usual adult non-renal regimen is a 200-mg initial dose followed by 100 mg every 12 hours over 60 minutes, but do not automatically apply that loading exposure above the renal daily cap. See the separately displayed institutional regimen and documented difference.

RDM34-official-minocycline-label-C1 · Source locator: Dosage and administration: adults and renal impairment; warnings for magnesium-containing formulation.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa
Retrieved
2026-09-07
Exact label title
Minocycline - MINOCIN IV renal label
DailyMed Set ID
e415c323-8219-464b-9e3e-72c5a796cdaa
Label revision
Prescribing text revised March 2025
Renal-function method
CrCl, mL/min; renal total-daily-dose ceiling.
Source date/version
Prescribing text revised March 2025
Hash meaning
SHA-256 of local authored summary only, not original HTML, PDF or SPL bytes.
Local summary SHA-256
b720fbfb8d968aa79d60da51fe2338ceece94cf1172b6f525816168647d3dcda
Separate professional-source layer

University and professional protocols

Professional

UCSF - systemic minocycline institutional strategy

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; systemic immediate-release oral or IV minocycline institutional regimen.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adults receive 200 mg IV/orally once, then 100 mg every 12 hours. UCSF makes no routine renal or hemodialysis reduction. Some selected infections may require 200 mg every 12 hours with ID/stewardship input.

This higher-dose expert strategy must be distinguished from product-label renal cautions and total-daily-dose limits. Do not apply it to extended-release acne products, topical products or an unreviewed formulation.

RDM30-044-minocycline-1 · Source locator: UCSF - systemic minocycline institutional strategy; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/minocycline
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
33ed52031b40bc83df8fd54353fd34aa586a452d1616cdfad707d1a2a4e90efd

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/minocycline/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
c8ada2a24c7808dea329456d1ecc7d8765f9ec31971fa5857ce9e22147145318
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report